A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Peplin
ClinicalTrials.gov Identifier:
NCT00942604
First received: July 19, 2009
Last updated: November 22, 2013
Last verified: November 2013
Results First Received: February 21, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Condition: Actinic Keratoses
Interventions: Drug: PEP005 (ingenol mebutate) Gel
Drug: Vehicle gel

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study period was 22 July 2009 (first patient randomized) to 14 October 2009 (last patient completed Day 57).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
PEP005 (Ingenol Mebutate) Gel PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
Vehicle Gel Vehicle gel once daily for 2 consecutive days

Participant Flow:   Overall Study
    PEP005 (Ingenol Mebutate) Gel     Vehicle Gel  
STARTED     100     103  
COMPLETED     98     99  
NOT COMPLETED     2     4  
Protocol Violation                 1                 1  
Adverse Event                 0                 1  
Withdrawal by Subject                 0                 1  
Patient relocation                 1                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
PEP005 (Ingenol Mebutate) Gel PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
Vehicle Gel Vehicle gel once daily for 2 consecutive days
Total Total of all reporting groups

Baseline Measures
    PEP005 (Ingenol Mebutate) Gel     Vehicle Gel     Total  
Number of Participants  
[units: participants]
  100     103     203  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     48     52     100  
>=65 years     52     51     103  
Gender  
[units: participants]
     
Female     41     35     76  
Male     59     68     127  
Region of Enrollment  
[units: participants]
     
United States     100     103     203  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions   [ Time Frame: 57 days ]

2.  Secondary:   Proportion of Patients With Partial Clearance of Actinic Keratoses (AK) Lesions   [ Time Frame: 57 days ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Dr. Torsten Skov
Organization: LEO Pharma
phone: +4520736294
e-mail: torsten.skov@leo-pharma.com


No publications provided by Peplin

Publications automatically indexed to this study:

Responsible Party: Peplin
ClinicalTrials.gov Identifier: NCT00942604     History of Changes
Other Study ID Numbers: PEP005-028
Study First Received: July 19, 2009
Results First Received: February 21, 2012
Last Updated: November 22, 2013
Health Authority: United States: Food and Drug Administration